Step by Step

INTRODUCTION

Pathology MOC Activity ID

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 0.50

Target Audience:

Pathologists, Pathology Residents, Medical Students, Pathology Assistants and Pathology Assistant Students.

Educational Objectives:

Upon completion of this activity, participants will be able to:

  • Increase awareness of the histologic and immunohistochemical features of clear cell carcinoma (CCC) of the ovary.
  • Identify the molecular aspects of CCC.
  • Evaluate the treatment options and prognosis of CCC.
SPECIAL NOTE:
There is no educational content to this course. This course is designed to supplement training that has already occurred. This course is designed to only administer the required post-test and collect CME evaluations.

This course is eligible for The American Board of Pathology SAM credit.

Suggested Additional Reading:

  1. Chan JK, Teoh D,Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370-6.
  2. Clement PB, Young RH. Atlas of Gynecologic Surgical Pathology. Third Edition.
  3. Köbel M, Kalloger SE, Carrick J, Huntsman D, et al. limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009 Jan;33(1):14-21.
  4. Yamamoto S., Tsuda H., Takano M., et al.: PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinomas. Virch Arch. 460:77-87 2012.
  5. Delair DF, Burke KA, Selenica P, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol. 2017 Oct;243(2):230-241.
  6. Shibuya Y, Tokunaga H, Saito S, et al. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Genes Chromosome Cancer. 2017 Oct 16 (Epub ahead of print). PMID: 29044863.
  7. Bennett JA, Dong F, Yong RH, et al. Clear cell carcinoma of the ovary evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases. Histopathology. 2015 May;66(6):808-15.
  8. Kim SI, et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31552-4.
  9. Gounaris I, Brenton JD. Molecular pathogenesis of ovarian clear cell carcinoma. Future Oncol. 2015;11(9):1389-405.
  10. Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol. 2002;10:332–338.
  11. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000 Sep;13(9):962-72.

Authors:
Min Han MD, PhD — Clinical Instructor at Magee Womens Hospital
No relationships with industry relevant to the content of this educational activity have been disclosed.
Rohit Bhargava, MD — Professor of Pathology, UPMC
No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.